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Introduction
Glucose -6-phosphate dehydrogenase (G6PD) deficiency
is the commonest genetic disorder and is one of the most
frequent red cell enzymopathies worldwide.1 It was
discovered in 1956 by Alving and his colleagues while
investigating the unusual primaquin sensitivity of
erythrocytes in Blacks.2 Later, it was discovered that G6PD
deficiency was not unique to Africans but was prevalent
in other ethnic groups as well. Nearly a decade after its
discovery, various associated clinical syndromes were
defined.
Epidemiology
It is estimated that 400 million people carry the defective
gene globally. Historically, geographical distribution of
G6PD deficiency parallels the endemicity of malaria.3
Hence, high prevalence is seen typically in Africa, Asia,
Mediterranean countries and Latin America.
Transmigration of population led to its worldwide
emergence. A recent meta-analysis showed a global
prevalence of 4.5% G6PD deficiency and indicated an
incidence of 1.8% in Pakistan.4 However, it ignored several
of our locally published non indexed papers that reported
an incidence of 2% to 4% in Pakistani males (Figure-1) with
a high incidence of 8% in Pathans.5-8 Two large national
studies reported that 26% and 30 % of all hospital
admissions respectively in 1624 and 6454 babies were
required for evaluation of neonatal jaundice.9,10 Low birth
weight, ABO or Rh incompatibility and sepsis were
recognized as important contributors for jaundice9 while
G6PD deficiency was observed in 8% of jaundiced babies.11
Structure and function of G6PD
G6PD is a dimer with each monomer having a molecular
weight of 59kDa and consisting of 515 amino acids. At
normal pH, G6PD molecule exists as a tetramer and each
subunit carries NADP[nicotine amide adenine
dinucleotide phosphate] has its own active site.12
Therefore, NADP can be considered both as a structural
and a functional domain of G6PD molecule. G6PD is the
enzyme catalyzing the first and the rate limiting step in
pentose phosphate pathway. The latter is the dominant
form of glycolysis in red cells. The enzyme assists
conversion of glucose 6 phosphate into 6-
phosphonogluconolactone and is a significant source of
NADPH [reduced form of NADP]. NADPH is crucial for red
cell survival and promotes glutathione reduction, catalase
stabilization thereby neutralizing their antioxidant
properties (Figure-2). In contrast to other cells,
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Figure-1: Prevalence of G6PD deficiency in Pakistan.6,8,23-28
Figure-2: Biochemical role of G6PD enzyme in the cells [GSH: reduced glutathione;
GSSG: oxidized glutathione; G6P: Glucose 6 phosphate; F6P: Fructose 6 phosphate;
NADP:nicotineamide adenine dinucleotide phosphate; NADPH:nicotineamide adenine
dinucleotide phosphate reduced].
erythrocytes lack mitochondria and therefore are
exclusively dependent on PPP as the only source of
NADPH in the body. Thus in the absence of G6PD and
therefore NADPH, erythrocytes cannot resist oxidative
stress and the accumulated free radicals precipitate their
untimely lysis.
Genetics and Inheritance
G6PD is present on the long arm of the X-chromosome
[Xq2.8] and therefore mode of inheritance is sex linked for
G6PD deficiency.1 Women who are heterozygous are the
carriers of defective genes and may have normal,
intermediate or severely low G6PD enzyme activity
depending on randomization of X-chromosome. There
are 400 G6PD variants reported so far. The most common
variant in Africans is regarded as G6PD A-(202A>G)
whereas G6PD 563C>T is the most frequent genotype in
southern Europe, Middle East countries and Indian sub-
continent.13 Recently, G6PD Mediterranean was reported
in 78% of Pakistanis with G6PD Chatham and Orissa being
less common14 confirming an earlier report.15 Associated
1311 C/T polymorphism was also observed in substantial
subjects with G6PD 563C>T.16
Patho-physiology of G6PD deficiency
Small quantities of enzyme produced by G6PD deficient
red cells are enough for their survival in normal
circumstances. However on challenging with oxidative
stress, these red cells lyse because of low NADPH
production. The haemolysis and therefore icterus is self-
limiting despite the continued stress as the older
erythrocytes with lowest enzyme activity are haemolysed
first.1,12 Young red cells or reticulocytes are rich in
enzymes and therefore are able to sustain the oxidative
stress. This is however not the explanation for icterus seen
in neonates. Evidence has indicated that it is poor hepatic
handling of unconjugated bilirubin rather than increased
haemolysis which significantly contributes towards
neonatal hyperbilirubinaemia.17 Additionally, focus has
been placed on UGT1A1 mutation of gene promoter or
coding region in G6PD gene producing a Gilbert like
condition in G6PD deficient infants.
Clinical Features
G6PD deficient subjects are asymptomatic unless
subjected to oxidative stresses induced by drug
administration, infections and ingestion of fava beans.1
Four syndromes are observed
1. Acute infection/drug induced haemolysis: Clinically
haemolysis is acute and intravascular leading to back
pain, icterus and haemoglobinuria. Jaundice is typically
associated with indirect bilirubinaemia in the presence of
normal hepatic enzymes.
2. Favism: Fava beans contain oxidants like glycosides,
divicine and isouramil and other unknown factors.18
Ingestion of fava beans lead to acute haemolysis in some
but not all G6PD deficient subjects.
3. Neonatal hyperbilirubinaemia: This is the most
devastating effect of G6PD deficiency19 with potential
threat to acute encephalopathy culminating in
permanent brain damage.
4. Chronic non spherocytic haemolytic anaemia [CNSHA]:
this is a rare and a severe form of G6PD deficiency. Unlike
the usual variant with episodic haemolysis on oxidative
challenges, subjects with CNSHA demonstrate chronic
haemolysis and splenomegaly.
Other clinical considerations
G6PD deficiency has been linked to susceptibility to
sepsis although not definitely proven. Complete absence
of G6PD deficiency is incompatible with life resulting in
early foetal loss.
Management
Lab Diagnosis
CBC shows normochromicnormocytic anaemia. White cell
count and platelets are typically normal but might by
minimally elevated secondary to haemolysis.
Reticulocytosis is marked and peripheral film typically
shows sphercoytes, polychromasia, bite and blister cells.
Indirect bilirubin and LDH are elevated as in any acute
haemolysis. The diagnostic test is G6PD enzyme assay.
This should be done when reticulocytosis has subsided as
newly formed red cells are well replenished with enzyme
and may give a false normal value during haemolysis.
Several screening tests are available such as dye
decolourization test, monospotflurorescent test,
methaemoglobin reduction test and formazan test. More
recently a novel cytofluorometric test based on
methaemoglobin has been devised.20 All these tests
evaluate the production of NADPH. G6PD quantitative
assay is also available in Pakistan. The reference ranges of
G6PD assay are 6.7-14.3, 5.8-13.5 and 7.0-19 U/gHb for
Pakistani adults, children and neonates respectively.
Carriers are difficult to diagnose through screening tests
as a heterozygote can have normal or near normal G6PD
activity.
Prevention: There are several drugs that can precipitate
haemolysis and need to be avoided.12 G6PD deficient
subjects should be given a list of these drugs which must
be avoided while prescribing medications to such
subjects. Recently, an evidence based literature addresses
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this issue21 and listed medications that do and donot
cause haemolysis (Table-1).
Treatment: Haemolysis seen in a G6PD deficient subject is
a limiting condition and does not require any treatment.
Severe rapid anaemia may warrant red cell transfusions.
Splenectomy is not required as haemolysis is mainly
intravascular.1,12
Future Directions
It is the nature of science to raise new questions as the old
ones are answered. We now have a comprehensive picture
of G6PD biochemical and molecular properties as well as
clinical and laboratory features of this enzymopathy. For
us, few questions are still unanswered: What are the
unknown variants of G6PD in our country besides G6PD
Mediterranean variant? What is the carrier rate in our
country? Should we screen all our neonates for G6PD
enzyme? Or should we just monitor icterus?22 A large
prospective study is needed for probing into these queries.
References
1. Beutler E. G6PD deficiency. Blood 1994; 84: 3613-36.
2. Alving AS, Tarlov AR, Brewer G, Carson PE, Keller-Meyer RW, Long
WK. Glucose-6-phosphate dehydrogenase deficiency: some
biological implications. Trans Assoc Am Physicians 1960; 73: 80-92.
3. Hedrick PW. Population genetics of malaria resistance in humans.
Heredity (Edinb) 2011; 107: 283-304.
4. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global
prevalence of glucose-6-phosphate dehydrogenase deficiency: a
systematic review and meta-analysis. Blood Cells Mol Dis 2009; 42:
267-78.
5. Saleem A. Glucose-6-phosphate dehydrogenase deficiency and
hemolytic anemia. J Pak Med Assoc 1966; 16: 3-9.
6. Ronald AR, Underwood BA, Woodward TE. Glucose-6-phosphate
dehydrogenase deficiency in Pakistani males. Trans R Soc Trop
Med Hyg 1968; 62: 531-3.
7. Stern MA, Kynoch PA, Lehmann H. Beta-thalassaemia, glucose-6-
phosphate-dehydrogenase deficiency, and haemoglobin D-
Punjab in Pathans. Lancet 1968; 1: 1284-5.
8. Ali N, Anwar M, Ayyub M, Bhatti FA, Nadeem M, Nadeem A.
Frequency of glucose-6-phosphate dehydrogenase deficiency in
some ethnic groups of Pakistan. J Coll Physicians Surg Pak 2005;
15: 137-41.
9. Tikmani SS, Warraich HJ, Abbasi F, Rizvi A, Darmstadt GL, Zaidi
AK. Incidence of neonatal hyperbilirubinemia: a population-
based prospective study in Pakistan. Trop Med Int Health 2010;
15: 502-7.
10. Rehman H, Khan MA, Hameed A, Roghani MT, Ahmad A.
Erythrocyte glucose 6 phosphate dehydrogenase deficiency and
neonatal jaundice. J Pak Med Assoc 1995; 45: 259-60.
11. Rehman H, Khan MA, Hameed A, Roghani MT, Ahmad A.
Erythrocyte glucose 6 phosphate dehydrogenase deficiency and
neonatal jaundice. J Pak Med Assoc 1995; 45: 259-60.
12. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase
deficiency. Lancet 2008; 371: 64-74.
13. Beutler E. G6PD: population genetics and clinical manifestations.
Blood Rev 1996; 10: 45-52.
14. Moiz B, Nasir A, Moatter T, Naqvi ZA, Khurshid M. Molecular
characterization of glucose-6-phosphate dehydrogenase deficiency
in Pakistani population. Int J Lab Hematol 2011; 33: 570-8.
15. Saha N, Ramzan M, Tay JS, Low PS, Basair JB, Khan FM. Molecular
characterisation of red cell glucose-6-phosphate dehydrogenase
deficiency in north-west Pakistan. Hum Hered 1994; 44: 85-9.
16. Moiz B, Nasir A, Moatter T, Naqvi ZA, Khurshid M. Population study
of 1311 C/T polymorphism of Glucose 6 Phosphate
Dehydrogenase gene in Pakistan - an analysis of 715 X-
chromosomes. BMC Genet 2009; 10: 41.
17. Kaplan M, Beutler E, Vreman HJ, Hammerman C, Levy-lahad E,
Renbaum P, et al. Neonatal hyperbilirubinemia in glucose-6-
phosphate dehydrogenase-deficient heterozygotes. Pediatrics
1999; 104: 68-74.
18. Azadbakht M, Hosseinimehr SJ, Shokrzadeh M, Habibi E, Ahmadi
A. Diospyros lotus L. fruit extract protects G6PD-deficient
erythrocytes from hemolytic injury in vitro and in vivo: prevention
of favism disorder. Eur Rev Med Pharmacol Sci 2011; 15: 1270-81.
19. Riskin A, Gery N, Kugelman A, Hemo M, Spevak I, Bader D.
Glucose-6-Phosphate Dehydrogenase Deficiency and Borderline
Deficiency: Association with Neonatal Hyperbilirubinemia. J
Pediatr 2012; 161: 191-6.
20. Shah SS, Diakite SA, Traore K, Diakir M, Kwiatkowski DP, Rockett
KA, et al. A novel cytofluorometric assay for the detection and
quantification of glucose-6-phosphate dehydrogenase
deficiency. Sci Rep 2012; 2: 299.
21. Youngster I, Arcavi L, Schechmaster R, Akayzen Y, Poplisti H,
Shimonov J, et al. Medications and glucose-6-phosphate
dehydrogenase deficiency: an evidence-based review. Drug Saf
2010; 33: 713-26.
22. Inati A, Abbas HA, Boumitri C, Tecle N. Prevalence of glucose-6-
phosphate dehydrogenase deficiency among neonates at a
tertiary care centre in Lebanon. J Med Screen 2012; 19: 103-4.
J Pak Med Assoc
503 B. Moiz
Table: Medications that are safe and harmful in G6PD deficiency.21
Group 1 Group 2 Group 3
Methyl blue Paracetamol Colchicine
Nitrofurantoin Aspirin Doxorubicin
Phenazopyridine Ascorbic acid Levodopa
Primaquin Chloroquin Doxorubicin
Dapsone Chloramphenicol Phenacetin
Rasburicase Ciprofloxacin Phenylbutazone
Toluidine blue Nalidixic acid Streptomycin
Quinine Vitamin K derivatives
Group 1: Medications that should be avoided.
Group 2: Medications that are safe in therapeutic doses.
Group 3: Medications having no evidence to contravene their usage.
